Biogen (BIIB) PT Lowered to $213 at RBC Capital
Get Alerts BIIB Hot Sheet
Price: $221.56 +4.24%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $213.00 (from $233.00) while maintaining a rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Toronto-Dominion Bank (TD:CN) (TD) PT Raised to Cdn$184 at CIBC
- Citi Upgrades Hong Kong & China Gas Co. Ltd. (3:HK) (HOKCY) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share